GlassScriptPhysician profile
Pedram Ghasri
NPI 1639429178
$16,142.56
in general payments reported to CMS, 2019-2025
54 companies · $3,907 in 2025
The $3,907 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,837 · 2020: $1,670 · 2021: $1,602 · 2022: $1,851 · 2023: $2,595 · 2024: $2,681 · 2025: $3,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,140 · Education: $42.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,140.24 |
| Education | $42.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,255.87 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,152.50 | 2019-2025 | Winlevi, Ilumya, Blu-U |
| Regeneron Healthcare Solutions, INC. | $1,086.49 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $995.38 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $964.27 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $962.03 | 2021-2025 | |
| Galderma Laboratories, L.P. | $919.75 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Pfizer INC. | $861.13 | 2019-2025 | |
| Janssen Biotech, INC. | $765.65 | 2020-2025 | Tremfya |
| Amgen INC. | $671.44 | 2020-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $532.36 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $463.09 | 2019-2025 | |
| 3m Company | $450.00 | 2019 | |
| Surgenex LLC | $392.67 | 2025 | Surgraft, Ardeograft, Pellograft |
| Lilly USA, LLC | $354.36 | 2019-2025 | Taltz, Olumiant, Ebglyss |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $345.19 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $320.25 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| Ucb, INC. | $240.45 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $212.18 | 2021-2025 | |
| Journey Medical Corporation | $203.88 | 2022-2025 | |
| Almirall LLC | $199.88 | 2019-2025 | Seysara, Klisyri |
| Merz North America, INC. | $195.00 | 2019-2022 | |
| Allergan, INC. | $171.63 | 2019-2021 | |
| Biofrontera INC. | $148.43 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.63 | 2023-2025 | Spevigo |
| Organogenesis INC. | $104.47 | 2021-2025 | Cygnus Dual |
| Epi Health, LLC | $99.14 | 2019-2022 | |
| Botanix Sb INC | $95.14 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $69.21 | 2024-2025 | Ycanth |
| Sanofi-Aventis U.S. LLC | $64.26 | 2020 | |
| Encore Dermatology INC. | $61.82 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $57.20 | 2022-2025 | Nuzyra |
| Aclaris Therapeutics, INC. | $53.73 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $53.62 | 2024 | Sotyktu |
| Vyne Pharmaceuticals INC. | $52.97 | 2020-2021 | |
| Organon LLC | $51.94 | 2025 | Vtama |
| Dermira, INC. | $50.22 | 2020-2021 | |
| Smith+Nephew, INC. | $46.43 | 2025 | Stravix Pl |
| Genentech USA, INC. | $40.88 | 2020-2023 | Erivedge |
| Integra Lifesciences Corporation | $39.91 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Solta Medical, A Division of Bausch Health US, LLC | $38.25 | 2019-2025 | Clear+Brilliant |
| Medimetriks Pharmaceuticals, INC. | $36.77 | 2025 | Genadur |
| Dusa Pharmaceuticals, INC. | $22.23 | 2019 | |
| Sandoz INC. | $20.55 | 2019 | |
| Cipher Pharmaceuticals US LLC | $19.21 | 2025 | Spinosad, Natroba |
| Blueprint Medicines Corporation | $18.33 | 2023 | |
| Merck Sharp & Dohme LLC | $17.33 | 2019 | |
| Strata Skin Sciences, INC. | $16.15 | 2021 | |
| Sebela Pharmaceuticals INC. | $15.32 | 2023 | Naftin |
| Icad, INC | $13.63 | 2022 | |
| Nabriva Therapeutics, Plc | $12.34 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedram Ghasri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.